PT Kalbe Farma Tbk. (FRA:LCLA)

Market Cap	1.69B -39.0%
Revenue (ttm)	1.85B +13.0%
Net Income	176.61M +5.8%
EPS	0.00 +6.8%
Shares Out	n/a
PE Ratio	9.57
Forward PE	8.90
Dividend	0.00 (2.40%)
Ex-Dividend Date	Jun 4, 2026

Volume	n/a
Open	0.0290
Previous Close	0.0400
Day's Range	0.0290 - 0.0400
52-Week Range	0.0235 - 0.0695
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In addition, the company provides health screening services; operates as ...

• Industry: Pharmaceutical Preparations
• Founded: 1966
• Employees: 12,806
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LCLA

Financial Performance

In 2025, PT Kalbe Farma Tbk.'s revenue was 35.32 trillion, an increase of 8.27% compared to the previous year's 32.63 trillion. Earnings were 3.66 trillion, an increase of 13.09%.

Financial numbers in IDR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 19, 2026

Data Sources Report a data error